Changes to this Summary (08/07/2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that the presence of the H3F3A K27M mutation occurs exclusively in diffuse high-grade pediatric astrocytomas (cited Gielen et al. as reference 35).
Added Gnekow et al. as reference 28.
Added text to state that a multicenter, phase III, placebo-controlled trial of 117 patients confirmed these earlier findings; 35% of the patients in the everolimus group had at least a 50% reduction in the size of the SEGA, versus no reduction in the placebo group (cited Franz et al. as reference 54 and level of evidence 1iDiv).
Added text to state that surveillance imaging will frequently identify asymptomatic recurrences (cited Udaka et al. as reference 4).
Added Gnekow et al. as reference 11.
Added Ononiwu et al. as reference 6.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.